Oral Oncology Reports最新文献_第4页

Early-stage oral cavity cancer (T1N0) with lymphatic drainage to the retropharyngeal lymph node: A therapeutic challenge 淋巴引流至咽后淋巴结的早期口腔癌（T1N0）：治疗挑战

Oral Oncology Reports Pub Date : 2025-01-21 DOI: 10.1016/j.oor.2025.100713

Simon E. Thurnheer , Martin W. Huellner , Deniz Kasikci , Grégoire B. Morand

引用次数: 0

Oligometastatic squamous cell carcinoma treated with and without involved site radiation 少转移性鳞状细胞癌有或没有受累部位放射治疗

Oral Oncology Reports Pub Date : 2025-01-09 DOI: 10.1016/j.oor.2024.100707

Allen M. Chen

{"title":"Oligometastatic squamous cell carcinoma treated with and without involved site radiation","authors":"Allen M. Chen","doi":"10.1016/j.oor.2024.100707","DOIUrl":"10.1016/j.oor.2024.100707","url":null,"abstract":"<div><h3>Purpose</h3><div>Comprising a heterogenous population, the optimal management of oligometastatic head and neck cancer is uncertain. We sought to report outcomes among patients treated with and without stereotactic body radiotherapy (SBRT) to local sites of disease.</div></div><div><h3>Methods and materials</h3><div>A review of institutional registries identified 49 patients with metastatic squamous cell carcinoma of the head and neck limited to 5 sites of disease or less. Patients with intact disease at primary local-regional sites; those treated by palliative radiation; and those who had previously received first-line systemic therapy were excluded.</div></div><div><h3>Results</h3><div>A total of 20 patients met eligibility criteria. Treatment included systemic therapy alone (10 patients) and systemic therapy with SBRT (10 patients). The median progression-free survival was 11 months and 6 months, respectively (p = 0.09). The 2-year overall survival was 29 % and 15 % for patients treated by SBRT and systemic therapy compared to systemic therapy alone, respectively (p = 0.21). There were no differences in the development of grade 3+ toxicity between the 2 groups, with the incidence of grade 3+ toxicity being 20 % and 30 % for patients treated with and without SBRT, respectively (p = 0.61).</div></div><div><h3>Conclusion</h3><div>Local SBRT was associated with trends in improved progression-free survival among patients with oligometastatic head and neck cancer. Prospective studies with larger datasets are warranted to further evaluate the role of this modality in this setting.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100707"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In response to Fiorillo: Agreeing on the need to rethink the demonization of AI writing tools such as ChatGPT 作为对Fiorillo的回应：同意有必要重新考虑对ChatGPT等人工智能写作工具的妖魔化

Oral Oncology Reports Pub Date : 2025-01-07 DOI: 10.1016/j.oor.2024.100712

Dag Øivind Madsen, Shahab Saquib Sohail

引用次数: 0

Insulin receptor substrate 1 (IRS 1) serum levels in patients with Oral Squamous Cell Carcinoma 口腔鳞状细胞癌患者血清胰岛素受体底物1 （IRS 1）水平

Oral Oncology Reports Pub Date : 2025-01-03 DOI: 10.1016/j.oor.2024.100708

Deeksheetha Prabhuvenkatesh , Karthikeyan Ramalingam , Pratibha Ramani , Selvaraj Jayaram

{"title":"Insulin receptor substrate 1 (IRS 1) serum levels in patients with Oral Squamous Cell Carcinoma","authors":"Deeksheetha Prabhuvenkatesh , Karthikeyan Ramalingam , Pratibha Ramani , Selvaraj Jayaram","doi":"10.1016/j.oor.2024.100708","DOIUrl":"10.1016/j.oor.2024.100708","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the expression of IRS 1 values in Oral Squamous Cell Carcinoma (OSCC) patients and its association with histological grading, tumor staging, and habits.</div></div><div><h3>Objective</h3><div>To assess the expression of IRS1 in patients with oral squamous cell carcinoma. To correlate IRS1 values with histological grading, tumor staging, habits, and overall survival in OSCC patients.</div></div><div><h3>Materials and methods</h3><div>IRS 1 values were assessed in N = 106 patients. IRS 1 values in 53 OSCC patients at preoperative and postoperative 3 months and were compared with 53 healthy controls using the sandwich ELISA method. The IRS 1 values were associated with clinicohistopathological factors. Statistical analysis was carried out using SPSS version 23.0 by IBM. One-way ANOVA and paired student t-tests were carried out and any p-value less than 0.05 was considered significant.</div></div><div><h3>Results</h3><div>The mean preoperative IRS 1 value in OSCC patients was 0.071 <em>±</em> 0.013, (p-value <0.001) and the mean postoperative 3 months IRS 1 value was 0.103 <em>±</em> 0.037 (p-value = 0.025). The mean IRS 1 value of healthy controls was 0.134 <em>±</em> 0.111 (p-value <0.001). The mean values in preoperative OSCC patients were underexpressed, compared to healthy controls and postoperative OSCC patients.</div></div><div><h3>Conclusion</h3><div>IRS1 expression was associated with various clinicopathological factors such as habit status, pathological tumor staging, and tumor grading. It was also found that underexpression of IRS1 was associated with poor prognosis of OSCC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100708"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to “The application of ChatGPT in the peer-reviewing process” 对“ChatGPT在同行评审过程中的应用”的回应

Oral Oncology Reports Pub Date : 2025-01-02 DOI: 10.1016/j.oor.2024.100709

Dag Øivind Madsen, Shahab Saquib Sohail

引用次数: 0

Integrating machine learning to customize chemotherapy for oral cancer patients 整合机器学习，为口腔癌患者定制化疗方案

Oral Oncology Reports Pub Date : 2024-12-31 DOI: 10.1016/j.oor.2024.100711

Saraswati Patel , Divya Yadav , Dheeraj Kumar

{"title":"Integrating machine learning to customize chemotherapy for oral cancer patients","authors":"Saraswati Patel , Divya Yadav , Dheeraj Kumar","doi":"10.1016/j.oor.2024.100711","DOIUrl":"10.1016/j.oor.2024.100711","url":null,"abstract":"<div><div>Oral cancer, particularly oral squamous cell carcinoma (OSCC), poses a significant global health burden, with over 350,000 new cases annually. Despite chemotherapy being critical for advanced-stage treatment, its lack of personalization often results in inconsistent responses, severe side effects, and limited efficacy. Current methodologies, such as rule-based systems and traditional statistical models, fail to account for the complex, nonlinear interactions between patient-specific factors and drug responses, underscoring the need for advanced solutions. This paper introduces a machine learning (ML)-driven framework to optimize chemotherapy regimens for oral cancer patients. By leveraging multi-modal datasets, including genomic profiles, clinical histories, tumor burden indices, and drug toxicity metrics, the proposed model achieves remarkable results. Utilizing an ensemble of random forests and neural networks, the framework achieves an accuracy of 92 %, outperforming existing ML methods (85 %) and traditional approaches (78 %). Additionally, it demonstrates a 25 % reduction in chemotherapy-induced toxicity and a 20 % decrease in treatment costs. Key innovations include a novel efficacy-toxicity trade-off metric and adaptability through reinforcement learning for real-time regimen refinement. To address data privacy concerns, the framework incorporates federated learning, ensuring scalability across diverse healthcare systems. Preliminary results highlight a 15–20 % improvement in treatment efficacy and a 10 % reduction in adverse effects compared to existing methods. This interdisciplinary approach bridges the gap between oncology and ML, offering a robust foundation for personalized medicine. By tailoring chemotherapy regimens, this framework aims to improve survival rates, minimize treatment-related complications, and enhance the quality of life for oral cancer patients globally.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100711"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms and diagnostic innovations in HPV-associated head and neck squamous cell carcinomas: Insights into integration, epigenetic modifications, and biomarker applications hpv相关头颈部鳞状细胞癌的分子机制和诊断创新：整合、表观遗传修饰和生物标志物应用的见解

Oral Oncology Reports Pub Date : 2024-12-27 DOI: 10.1016/j.oor.2024.100710

Geetha Shanmugam , Gnanaprakash Jeyaraj , Koustav Sarkar

引用次数: 0

Neoadjuvant cytokine (IRX-2) immunotherapy for resectable oral cavity carcinoma: Final results of the INSPIRE trial 可切除口腔癌的新辅助细胞因子（IRX-2）免疫治疗：INSPIRE试验的最终结果

Oral Oncology Reports Pub Date : 2024-12-26 DOI: 10.1016/j.oor.2024.100706

Gregory T. Wolf , Emily Bellile , Celine Mauquoi , Ariane Nguyen , Maureen Sartor , Siyu Liu , Laura Rozek , Jonathan B. McHugh

{"title":"Neoadjuvant cytokine (IRX-2) immunotherapy for resectable oral cavity carcinoma: Final results of the INSPIRE trial","authors":"Gregory T. Wolf , Emily Bellile , Celine Mauquoi , Ariane Nguyen , Maureen Sartor , Siyu Liu , Laura Rozek , Jonathan B. McHugh","doi":"10.1016/j.oor.2024.100706","DOIUrl":"10.1016/j.oor.2024.100706","url":null,"abstract":"<div><div>Oral cavity squamous carcinoma is characterized by alterations in cell mediated tumor immunity including a lack of immune reactive tumor infiltrating lymphocytes (TILs). To determine if a novel neoadjuvant injection of a multi-cytokine biologic (IRX-2) can restore immune reactivity and enhance patient survival, a randomized Phase 2 clinical trial was conducted in patients with Stage II-IV OSCC undergoing surgical resection (NCT 02609386).</div><div>The intention-to-treat (ITT) enrollment included 105 previously untreated patients, however 9 were excluded from the secondary endpoint analysis group for wrong histology, no treatment or patient refusal. A total of 96 patients comprised the final analytic group and were randomized (2:1) to receive the IRX-2 regimen (Regimen 1) compared to the identical regimen without IRX-2 cytokines (Regimen 2). Toxicity, tumor and immune responses, event-free (EFS) and overall (OS) survival were determined. Kaplan-Meier estimates for OS and EFS and inferential comparisons and asymptotoic log-rank testing between the two treatments were determined.</div><div>In prior preliminary analysis, significant increases in TILs and DMBT1 gene expression were noted for the IRX arm. No significant correlations of immunologic or tumor responses with survival outcomes were found. For the ITT population (n = 105) there were no significant differences in OS by treatment arm. OS [95 % CI] at 48 mo. was 70.4 [57.6, 80.0] vs 66.3 [47.5, 79.8] mos. (Regimen 1 vs Regimen 2, respectively).</div></div><div><h3>Conclusions</h3><div>Significant differences in survival were not seen, however, the trial demonstrated the feasibility of the neoadjuvant immunotherapy and differing immune modulation in each treatment arm. No correlations of immune biomarkers or tumor size changes with survival outcomes were identified.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100706"},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of ctDNA on metastatic cancer management: Current trends and future directions ctDNA对转移性癌症治疗的影响：当前趋势和未来方向

Oral Oncology Reports Pub Date : 2024-12-16 DOI: 10.1016/j.oor.2024.100705

Omveer Singh , Usha Kumari Sah , Jay Chandra , Saraswati Patel

引用次数: 0

Extended total semiconservative parotidectomy with skull base resection 扩大半保留性腮腺全切除术加颅底切除术

Oral Oncology Reports Pub Date : 2024-12-15 DOI: 10.1016/j.oor.2024.100701

Bipin Thomas Varghese

引用次数: 0